a Department of Nuclear Medicine , University Hospital Frankfurt am Main , Frankfurt am Main , Germany.
Int J Hyperthermia. 2018 Aug;34(5):639-643. doi: 10.1080/02656736.2018.1453552.
The aim of this study was to first assess the feasibility of bipolar radiofrequency ablation in patients with parathyroid adenoma.
Bipolar RFA was performed in 9 patients with primary parathyroid adenoma in one single session. Measured parameters were PTH and calcium serum levels prior to and after bRFA. Furthermore, using an NRS pain scale (1-10), the individual, subjective maximum sensation of pain was documented.
The bRFA resulted in a highly significant (p = .003906) decrease of serum PTH levels (median 67 ng/l) in comparison to those prior to the intervention (median 199 ng/l). Regarding calcium levels, there was no statistical significance (p = .460938), with a decrease of median serum levels comparing pre- and post-bRFA values from 2.82 mmol/l to 2.66 mmol/l. The evaluation of the individual pain sensation during the procedure was assessed by the patients with a median of 5/10 on the NRS scale. In none of the 9 cases complications such as infections, persisting pain or nerve injury occurred.
For the first time, it was possible to depict the successful therapy of parathyroid adenoma by means of bRFA. This work thus proves bRFA to be an effective, safe, applicable and, concerning sensation of pain, very well tolerable thermoablative technique in the treatment of parathyroid adenoma.
本研究旨在首先评估使用双极射频消融术治疗甲状旁腺腺瘤的可行性。
对 9 例原发性甲状旁腺腺瘤患者在单次治疗中进行双极 RFA。测量的参数是 bRFA 前后的血清甲状旁腺激素（PTH）和钙水平。此外，使用 NRS 疼痛量表（1-10）记录患者个体的最大主观疼痛感觉。
bRFA 使血清 PTH 水平（中位数 67ng/l）与介入前相比（中位数 199ng/l）显著降低（p = .003906）。关于钙水平，无统计学意义（p = .460938），bRFA 前后血清中位数水平从 2.82mmol/l 下降至 2.66mmol/l。患者通过 NRS 量表评估术中的个体疼痛感觉，中位数为 5/10。9 例患者均无感染、持续疼痛或神经损伤等并发症。
本研究首次成功地通过 bRFA 治疗甲状旁腺腺瘤。因此，bRFA 被证明是一种有效、安全、适用的热消融技术，且在治疗甲状旁腺腺瘤时疼痛感觉可耐受。
